Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Naresh BummaJoshua RichterSundar JagannathHans C LeeJames E HoffmanAttaya SuvannasankhaJeffrey A ZonderMansi R ShahSuzanne LentzchRachid C BazJoseph J MalySwathi NamburiMatthew J PiankoJing Christine YeKa Lung WuRebecca W SilbermannChang-Ki MinMarie-Christiane VekemansMarkus MunderJa Min ByunJoaquin Martinez LopezKaniel CassadyMichelle DeVeauxDhruti ChokshiAnita BoyapatiAnasuya HazraGeorge D YancopoulosL Andres SirulnikKaren Rodriguez LorencGlenn S KroogYariv HouvrasMadhav V DhodapkarPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.